WO2004082699A3 - Verwendung von weihrauch oder seinen hydrierungsprodukten zur prophylaxe und/oder behandlung von zerebraler ischämie und/oder schädel/hirntrauma - Google Patents

Verwendung von weihrauch oder seinen hydrierungsprodukten zur prophylaxe und/oder behandlung von zerebraler ischämie und/oder schädel/hirntrauma Download PDF

Info

Publication number
WO2004082699A3
WO2004082699A3 PCT/EP2004/002839 EP2004002839W WO2004082699A3 WO 2004082699 A3 WO2004082699 A3 WO 2004082699A3 EP 2004002839 W EP2004002839 W EP 2004002839W WO 2004082699 A3 WO2004082699 A3 WO 2004082699A3
Authority
WO
WIPO (PCT)
Prior art keywords
cerebral
incense
treating
preventing
derivatives
Prior art date
Application number
PCT/EP2004/002839
Other languages
English (en)
French (fr)
Other versions
WO2004082699A2 (de
Inventor
Frank Striggow
Werner Schmidt
Till Mack
Original Assignee
Keyneurotek Ag
Frank Striggow
Werner Schmidt
Till Mack
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2003111921 external-priority patent/DE10311921A1/de
Priority claimed from DE2003111920 external-priority patent/DE10311920A1/de
Priority claimed from DE10331750A external-priority patent/DE10331750A1/de
Application filed by Keyneurotek Ag, Frank Striggow, Werner Schmidt, Till Mack filed Critical Keyneurotek Ag
Priority to EP04721524A priority Critical patent/EP1603583A2/de
Priority to US10/549,323 priority patent/US7645461B2/en
Publication of WO2004082699A2 publication Critical patent/WO2004082699A2/de
Publication of WO2004082699A3 publication Critical patent/WO2004082699A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung betrifft die Verwendung der Hydrierungsprodukte von Weihrauch (Olibanum), dessen hydrierten Inhaltsstoffen sowie physiologisch annehmbaren Salzen und Derivaten davon sowie von hydrierten Weihrauchextrakten zur Herstellung eines Arzneimittels zur prophylaktischen und/oder therapeutischen Behandlung von zerebraler Ischämie, Schädel/Hirntrauma und/oder Alzheimer-Krankheit. Erfindungsgemäss wird ferner die Verwendung von Weihrauch, Weihrauchextrakt, in Weihrauch enthaltenen Substanzen, ihren physiologisch annehmbaren Salzen, ihren Derivaten und deren physiologischen Salzen, reine Boswellinsäuren, Tirucallensäuren oder andere Triterpene, ihre physiologisch annehmbaren Salze, Derivate oder deren Salze zur Herstellung eines Arzneimittels zur prophylaktischen und/oder therapeutischen Behandlung von zerebraler Ischämie und/oder Schädel/Hirntrauma zur Verfügung gestellt.
PCT/EP2004/002839 2003-03-18 2004-03-18 Verwendung von weihrauch oder seinen hydrierungsprodukten zur prophylaxe und/oder behandlung von zerebraler ischämie und/oder schädel/hirntrauma WO2004082699A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04721524A EP1603583A2 (de) 2003-03-18 2004-03-18 Verwendung von weihrauch oder seinen hydrierungsprodukten zur prophylaxe und/oder behandlung von zerebraler ischemie und/oder schedel/hirntrauma
US10/549,323 US7645461B2 (en) 2003-03-18 2004-03-18 Method of treating cerebral ischemia with hydrogenation products of frankincense extracts

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE10311921.3 2003-03-18
DE2003111921 DE10311921A1 (de) 2003-03-18 2003-03-18 Verwendung von Weihrauch zur Behandlung von zerebraler Ischämie
DE2003111920 DE10311920A1 (de) 2003-03-18 2003-03-18 Verwendung von Weihrauch zur Behandlung von Schädel/Hirntrauma
DE10311920.5 2003-03-18
DE10331750A DE10331750A1 (de) 2003-07-14 2003-07-14 Verwendung der Hydrierungsprodukte von Weihrauch (Olibanum) zur Prophylaxe und/oder Behandlung von zerebraler Ischämie, Schädel/Hirntrauma und/oder Alzheimer-Krankheit
DE10331750.3 2003-07-14

Publications (2)

Publication Number Publication Date
WO2004082699A2 WO2004082699A2 (de) 2004-09-30
WO2004082699A3 true WO2004082699A3 (de) 2005-02-10

Family

ID=33032851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/002839 WO2004082699A2 (de) 2003-03-18 2004-03-18 Verwendung von weihrauch oder seinen hydrierungsprodukten zur prophylaxe und/oder behandlung von zerebraler ischämie und/oder schädel/hirntrauma

Country Status (3)

Country Link
US (1) US7645461B2 (de)
EP (1) EP1603583A2 (de)
WO (1) WO2004082699A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0913499B1 (pt) 2008-09-15 2020-03-17 Laila Nutraceuticals Composições anti-inflamatórias sinergísticas compreendendo extratos de boswellia serrata
DE102009004436A1 (de) * 2008-10-15 2010-04-29 Aureliasan Gmbh Verwendung einer Tirucallensäure, einer Lupansäure oder einer Robursäure als Arzneimittel
CN104922183B (zh) * 2009-07-18 2020-04-21 康普顿发展有限公司 炎症性疾病的抑制剂
US12005094B2 (en) 2009-07-18 2024-06-11 Compton Developments Ltd. Inhibitor of inflammatory conditions
US10940175B2 (en) 2009-07-18 2021-03-09 Compton Developments Ltd. Inhibitor of inflammatory conditions
US8828377B2 (en) 2010-03-15 2014-09-09 Laila Nutraceuticals Boswellia oil, its fractions and compositions for enhancing brain function
WO2012177825A1 (en) 2011-06-21 2012-12-27 Bvw Holding Ag Medical device comprising boswellic acid

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1113807A (zh) * 1994-06-15 1995-12-27 王万树 一种抗头痛中成药及其制备方法
US5720975A (en) * 1994-12-13 1998-02-24 Etzel; Rainer Use of incense in the treatment of alzheimer's disease
US6280751B1 (en) * 1997-03-10 2001-08-28 Jane Clarissa Fletcher Essential oil composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1113807A (zh) * 1994-06-15 1995-12-27 王万树 一种抗头痛中成药及其制备方法
US5720975A (en) * 1994-12-13 1998-02-24 Etzel; Rainer Use of incense in the treatment of alzheimer's disease
US6280751B1 (en) * 1997-03-10 2001-08-28 Jane Clarissa Fletcher Essential oil composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199739, Derwent World Patents Index; Class B04, AN 1997-416200, XP002291633 *
KRECK C ET AL: "[Herbal drugs of foreign cultures and medical systems exemplified by Indian incense. Considerations regarding social and insurance medicine expert assessment]", VERSICHERUNGSMEDIZIN / HERAUSGEGEBEN VON VERBAND DER LEBENSVERSICHERUNGS-UNTERNEHMEN E.V. UND VERBAND DER PRIVATEN KRANKENVERSICHERUNG E.V. 1 SEP 1999, vol. 51, no. 3, 1 September 1999 (1999-09-01), pages 122 - 127, XP009032578, ISSN: 0933-4548 *
SAFAYHI H ET AL: "PHARMAKOLOGISCHE ASPEKTE VON WEIHRAUCH UND BOSWELLIASAEUREN", PHARMAZEUTISCHE ZEITUNG, FRANKFURT, DE, vol. 142, no. 39, 1997, pages 11 - 20, XP000912127, ISSN: 0031-7136 *

Also Published As

Publication number Publication date
US20060177467A1 (en) 2006-08-10
WO2004082699A2 (de) 2004-09-30
EP1603583A2 (de) 2005-12-14
US7645461B2 (en) 2010-01-12

Similar Documents

Publication Publication Date Title
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
CA2427227A1 (en) Lactam compound
DE69906518D1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
ES2153906T3 (es) Uso de incienso para el tratamiento de la enfermedad de alzheimer.
WO2007016679A3 (en) Combination immediate release controlled release levodopa and carbidopa dosage forms
ECSP034518A (es) Nuevos retinoides para el tratamiento de enfisema
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
AU7425391A (en) Use of n-alkylated 1, 4-dihydropyridinedicarboxylic acid esters as medicaments, new compounds and processes for their preparation
HK1104280A1 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2004082699A3 (de) Verwendung von weihrauch oder seinen hydrierungsprodukten zur prophylaxe und/oder behandlung von zerebraler ischämie und/oder schädel/hirntrauma
CL2004001068A1 (es) Compuestos derivados de 2,3,4,5-tetrahidrobenzo[f][1,4]oxazepina; procedimientos de preparacion; composicion farmaceutica que los contiene y su uso en la elaboracion de un medicamento util para el tratamiento de la enfermedad de alzheimer.
AR001765A1 (es) Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
WO1999020291A3 (en) Pharmaceutical grade ginkgo biloba
WO2000015207A3 (en) Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
IL164763A0 (en) Byperforin derivatives, the use thereof and formulations containing them
DE60004093D1 (de) Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
WO2002036105A3 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
EP1232748A4 (de) Subsituierte nitrobenzol derivate mit medikamentöser oder anderer wirkung
UY26950A1 (es) Nuevos retinoides para el tratamiento del enfisema
GEP20043356B (en) Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004721524

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006177467

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10549323

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004721524

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10549323

Country of ref document: US